argenx SE American Depositary Receipt (1AEA)
XHAN
Real-time Data
06:00 AM
Day's Range
785.0052 wk Range
560.00Overview - 1AEA - argenx SE American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
-3.44B
P/E (Trailing)
‪39.61‬
EV / EBITDA
‪-2.79‬
Profitability
Gross Margin
‪90.42%‬
Profit Margin
‪89.14%‬
Operating Margin
‪30.88%‬
Return on Assets
‪14.88%‬
Return on Equity
‪17.64%‬
Ownership
Shares Outstanding
62.53M
Price stats
50-Day Avg
‪819.10‬
200-Day Avg
‪722.38‬
Peers - 1AEA - argenx SE American Depositary Receipt
Peer Comparison
Compared with companies in Biotechnology listed on XHAN.
- 1AEAXHANargenx SE American Depositary Receipt+27.55%52-week change39.61P/E (Trailing)‪89.14%‬Profit Margin
- 2X2X10XHAN2X10+95.05%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 2X2X1XHAN2X1+94.58%52-week change-19.93P/E (Trailing)‪0.00%‬Profit Margin
- 5N5NRXHAN5NR+89.13%52-week change—P/E (Trailing)‪-73.51%‬Profit Margin
- 1O1OTXHAN1OT+88.05%52-week change-9.83P/E (Trailing)‪-240.12%‬Profit Margin
- 4E4E2XHAN4E2+94.61%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0QFXHANModerna Inc.+87.66%52-week change-23.74P/E (Trailing)‪54.83%‬Profit Margin
Profile Summary - 1AEA - argenx SE American Depositary Receipt
About
argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
